VGT ETF Climbs 0.7%
Dow Jones2026/10/28 20:36This article was automatically generated using Dow Jones technology.
Shares of Vanguard Information Technology ETF rose 0.7% to $123.59 Wednesday on what proved to be an overall positive trading session for the U.S. stock market, with the S&P 500 Index rising 0.3% to 7,743.98.
This was the fund's fourth consecutive day of gains.
The ETF's shares closed 5.4% below the 52-week high of $130.66 seen on October 6, 2026.
Trading volume was 3,446,314, compared to the 65-day average trading volume of 4,115,445.
As of October 27, the fund's net asset value totaled $122.79 per share.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 28, 2026 16:36 ET (20:36 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.